Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Related Citations for PubMed (Select 24933366)


Quantitative proteomic analysis identifies targets and pathways of a 2-aminobenzamide HDAC inhibitor in friedreich's ataxia patient iPSC-derived neural stem cells.

Shan B, Xu C, Zhang Y, Xu T, Gottesfeld JM, Yates JR 3rd.

J Proteome Res. 2014 Nov 7;13(11):4558-66. doi: 10.1021/pr500514r. Epub 2014 Jun 26.


Mechanism of Action of 2-Aminobenzamide HDAC Inhibitors in Reversing Gene Silencing in Friedreich's Ataxia.

Soragni E, Chou CJ, Rusche JR, Gottesfeld JM.

Front Neurol. 2015 Mar 5;6:44. doi: 10.3389/fneur.2015.00044. eCollection 2015.


Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing.

Xu C, Soragni E, Chou CJ, Herman D, Plasterer HL, Rusche JR, Gottesfeld JM.

Chem Biol. 2009 Sep 25;16(9):980-9. doi: 10.1016/j.chembiol.2009.07.010.


Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.

Soragni E, Xu C, Cooper A, Plasterer HL, Rusche JR, Gottesfeld JM.

Methods Mol Biol. 2011;793:495-508. doi: 10.1007/978-1-61779-328-8_32.


Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model.

Rai M, Soragni E, Chou CJ, Barnes G, Jones S, Rusche JR, Gottesfeld JM, Pandolfo M.

PLoS One. 2010 Jan 21;5(1):e8825. doi: 10.1371/journal.pone.0008825.


Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo.

Beconi M, Aziz O, Matthews K, Moumné L, O'Connell C, Yates D, Clifton S, Pett H, Vann J, Crowley L, Haughan AF, Smith DL, Woodman B, Bates GP, Brookfield F, Bürli RW, McAllister G, Dominguez C, Munoz-Sanjuan I, Beaumont V.

PLoS One. 2012;7(9):e44498. doi: 10.1371/journal.pone.0044498. Epub 2012 Sep 4.


Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.

Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, Sangrey GR, Darnell SB, Plasterer H, Sadri-Vakili G, Gottesfeld JM, Thompson LM, Rusche JR, Marsh JL, Thomas EA.

Neurobiol Dis. 2012 May;46(2):351-61.


Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia.

Gottesfeld JM, Rusche JR, Pandolfo M.

J Neurochem. 2013 Aug;126 Suppl 1:147-54. doi: 10.1111/jnc.12302. Review.


Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3.

Chan PK, Torres R, Yandim C, Law PP, Khadayate S, Mauri M, Grosan C, Chapman-Rothe N, Giunti P, Pook M, Festenstein R.

Hum Mol Genet. 2013 Jul 1;22(13):2662-75. doi: 10.1093/hmg/ddt115. Epub 2013 Mar 7.


Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease.

Moumné L, Campbell K, Howland D, Ouyang Y, Bates GP.

PLoS One. 2012;7(2):e31080. doi: 10.1371/journal.pone.0031080. Epub 2012 Feb 8.


Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.

Kazantsev AG, Thompson LM.

Nat Rev Drug Discov. 2008 Oct;7(10):854-68. doi: 10.1038/nrd2681. Review.


Quantitative profiling and identification of differentially expressed plasma proteins in Friedreich's ataxia.

Swarup V, Srivastava AK, Padma MV, Rajeswari MR.

J Neurosci Res. 2013 Nov;91(11):1483-91. doi: 10.1002/jnr.23262. Epub 2013 Aug 30.


Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.

Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, Mangiameli A, Pennisi G, Stella AM, Butterfield DA.

J Neurol Sci. 2005 Jun 15;233(1-2):145-62. Review.


Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors.

Koppel I, Timmusk T.

Neuropharmacology. 2013 Dec;75:106-15. doi: 10.1016/j.neuropharm.2013.07.015. Epub 2013 Aug 2.


Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model.

Sandi C, Pinto RM, Al-Mahdawi S, Ezzatizadeh V, Barnes G, Jones S, Rusche JR, Gottesfeld JM, Pook MA.

Neurobiol Dis. 2011 Jun;42(3):496-505. doi: 10.1016/j.nbd.2011.02.016. Epub 2011 Mar 17.


Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model.

Quinti L, Chopra V, Rotili D, Valente S, Amore A, Franci G, Meade S, Valenza M, Altucci L, Maxwell MM, Cattaneo E, Hersch S, Mai A, Kazantsev A.

PLoS Curr. 2010 Sep 2;2. pii: RRN1172. doi: 10.1371/currents.RRN1172.


Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.

Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM.

Nat Chem Biol. 2006 Oct;2(10):551-8. Epub 2006 Aug 20. Erratum in: Nat Chem Biol. 2007 Jul;3(7):432.


SAHA Capture Compound--a novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders.

Fischer JJ, Michaelis S, Schrey AK, Diehl A, Graebner OY, Ungewiss J, Horzowski S, Glinski M, Kroll F, Dreger M, Koester H.

Proteomics. 2011 Oct;11(20):4096-104. doi: 10.1002/pmic.201000717. Epub 2011 Sep 7.


Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise.

Mai A, Rotili D, Valente S, Kazantsev AG.

Curr Pharm Des. 2009;15(34):3940-57.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk